Therefore, the observed increase in CXCL13+CD8+ T cells in the PPCT-P group suggests that anti-PD-1 blockade when combined with nCRT may drive the expansion of tumor-specific CD8+ T cells. This evidence concerns the gene PDCD1 and neoplasm.